Non-thrombogenic medical article and a method for its preparation

• US 4,118,485 A
• Filed: 03/15/1976
• Issued: 10/03/1978
• Est. Priority Date: 03/20/1975
• Status: Expired due to Term

• Current Assignee: Aminkemi AB
• Original Assignee: Aminkemi AB
• Inventors: Eriksson, Jan-Christer, Larsson, Rolf, Rosengren, Ake, Hjelte, Maj-Britt
• Primary Examiner(s): Jiles, Henry R.
• Assistant Examiner(s): Owens, Cary
• Application Number:
  US05/666,943
• Time in Patent Office: 932 Days
• Field of Search: 424/183, 427/2, 427/3, 427/4, 117/47 A, 536/1, 536/4
• US Class Current: 514/56
• CPC Class Codes: A61L 17/005 containing a biologically active substance, e.g. a medicament or a biocide
• CPC Class Codes: A61L 2300/42 Anti-thrombotic agents, anticoagulants, anti-platelet agents
• CPC Class Codes: A61L 2300/606 Coatings
• CPC Class Codes: A61L 2300/802 Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
• CPC Class Codes: A61L 33/0017 using a surface active agent
• CPC Class Codes: C08B 37/0075 Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof

Abstract

A medical article is made non-thrombogenic by means of a surface coating containing heparin. The heparinized surface is stabilized by being contacted first with a cationic surfactant of the primary amine type and, subsequently, with a dialdehyde.

Claims

1. A medical article for use in contact with blood having a surface coating containing heparin to prevent thrombosis upon contact with blood, said surface coating also containing Schiff'"'"'s bases with low solubility formed by the reaction of a dialdehyde and a primary amine, the molecules of said Schiff'"'"'s bases being interspersed between the heparin molecules having partially blocked anionic groups in said surface coating to prevent substantial release of heparin from said surface coating upon contact with blood.

2. A medical article as claimed in claim 1, in which the dialdehyde is taken from the group consisting of OHC--CHO and OHC--R--CHO in which R represents 1-4 CH₂ groups.

3. A medical article as claimed in claim 2, in which the dialdehyde is glutardialdehyde, OHC--(CH₂)₃ --CHO.

4. A medical article as claimed in claim 1, in which the primary amine is of the type RNH₂ in which R is alkyl with 14-22, preferably 16-18 carbon atoms.

5. A medical article as claimed in claim 1, in which the ammonium salt of the primary amine has a critical micelle concentration lower than 5·

10^-3 mol/liter.

15. An article as claimed in claim 1 in which the heparinized surface is produced by using a solution of a complex compound of heparin and a cationic surfactant of the quaternary amine type.

16. An article as claimed in claim 1 in which the heparinized surface is produced by using a solution of a complex compound of heparin and alkyl-ammonium salt.

17. An article as claimed in claim 1 in which the heparinized surface is produced by treating the surface first with a solution of an alkyl-ammonium salt and then with a heparin solution.

25. A medical article according to claim 1 wherein the amount of the Schiff'"'"'s bases contained in the surface coating is such that the release of heparin from said surface coating after contact with blood for about 15 minutes at room temperature is not more than about 0.02 IU per square centimeter surface.

6. The method of stabilizing a heparinized surface to prevent release of heparin upon contact with blood, comprising treating the heparin with a cationic primary amine surfactant to block the anionic groups of the heparin and contacting the surface containing such blocked heparin with a dialdehyde to form in said surface Schiff'"'"'s bases having a low solubility and to partially unblock the anionic groups of the heparin.

7. The method as claimed in claim 6, comprising reacting heparin with a cationic primary alkylammonium salt to form an insoluble complex compound in which the anionic groups of the heparin are blocked by said cationic salt, dissolving said complex compound in a mixed organic solvent containing a non-polar and a polar solvent, contacting the surface with the solution thus produced to form a liquid film coating on the surface, evaporating the solvent from said coating, and contacting said coating with an aqueous solution of the dialdehyde.

8. The method as claimed in claim 6, comprising treating the heparin with the cationic primary amine surfactant until a substantially complete blocking of all anionic groups of the heparin has taken place, as indicated by the absence of pink color when testing with toluidene blue in accordance with the toluidene blue test.

9. The method as claimed in claim 6 characterized in that a cationic primary amine surfactant is used having a critical micelle concentration which is lower than about 5·

10^-3 mol/liter.

10. The method as claimed in claim 9, comprising treating the heparin with an aqueous solution of the cationic primary amine surfactant in a concentration exceeding the critical micelle concentration, at a temperature exceeding the Krafft temperature.

11. The method as claimed in claim 6, comprising treating the heparin with an alkyl amine hydrochloride having 14 to 22, preferably 16 to 18, carbon atoms in the alkyl group.

12. The method as claimed in claim 6, comprising treating the surface containing blocked heparin with glutardialdehyde.

13. The method as claimed in claim 6 for stabilizing a heparin layer linked by means of ionic bonds to a polymer surface comprising contacting the heparin layer with a 0.5 mM aqueous solution of cetyl amine hydrochloride or octadecyl amine hydrochloride at 60°

C. for 15 minutes and contacting the surface thus produced with a 0.5% aqueous solution of glutardialdehyde at 55°

C. for 20 minutes.

14. The method as claimed in claim 7, comprising mixing 100 parts by volume of an aqueous solution of heparin containing 300 mg (40,000 IU) per 100 ml at 60°

C. with 100 parts by volume of 17.6 millimole per liter aqueous solution of an alkyl amine hydrochloride having 16-18 carbon atoms in the alkyl chain, separating the resulting insoluble complex compound of heparin and alkyl amine hydrochloride from the solution, dispersing said complex compound in 120 parts by volume of cyclohexane, gradually adding 64 parts by volume of ethanol while stirring, adding 40 parts by volume of dichloroethane to the solution thus produced, filtering the resulting solution, applying the solution thus obtained to the surface of an article to be made non-thrombogenic so as to form a surface coating on said article, evaporating the solvent from said surface coating, and contacting the surface coating with a 0.5% aqueous solution of glutardialdehyde at 55°

C. for 20 minutes.

18. The method as claimed in claim 6 wherein the heparinized surface is produced by using a solution of a complex compound of heparin and a cationic surfactant of the quaternary amine type.

19. The method as claimed in claim 6 wherein the heparinized surface is prepared using a solution of a complex compound of heparin and alkyl-ammonium salt.

20. The method of claim 6 wherein the heparinized surface is prepared by treating the surface first with a solution of an alkyl-ammonium salt and then with a heparin solution.

21. An article having a heparinized surface prepared by the method of claim 6.

22. An article having a heparinized surface prepared by the method of claim 8.

23. An article having a heparinized surface prepared by the method of claim 11.

24. An article having a heparinized surface prepared by the method of claim 9.